Dr. Jun Zhang
Claim this profileHouston Methodist Hospital
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
28 reported clinical trials
43 drugs studied
About Jun Zhang
Education:
- Received MD from Hunan Medical University, China.
Experience:
- Completed Internal Medicine Residency at New Hanover Medical Center, Wilmington, NC.
- Undertook Hematology-Oncology Fellowship at Brody School of Medicine, East Carolina University.
- Holds a faculty position at Baylor College of Medicine.
- Program Director of the Hematology-Oncology Fellowship at Houston Methodist Hospital since 2018.
- Focuses on thoracic oncology and head & neck cancer clinical research.
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage I
2Non-Small Cell Lung Cancer
PD-L1 positive
Stage III
PD-L1 negative
Affiliated Hospitals
Clinical Trials Jun Zhang is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
IBI343
for Cancer
This is a Phase Ia/Ib, multicenter, open-label, first-in-human study to evaluate the safety, tolerability, PK, and efficacy of IBI343 in participants with locally advanced unresectable or metastatic solid tumors. It is planned to be carried out in different countries or regions such as China, Australia and US. There are three parts in phase Ia. Part 1 includes dose escalation and expansion phase and part 2 is designed for dose optimization for IBI343 monotherapy. Part 3 1L G/GEJ AC and 1L PDAC cohorts will include an initial safety lead-in stage to confirm the tolerability of IBI343 in combination with chemotherapy in 1L PDAC and G/GEJ AC, followed by a randomized dose-optimization stage designed to further characterize safety, pharmacokinetics, and preliminary efficacy to inform selection of the recommended Phase 3 dose. Part 3 metabolite profiling cohort is designed to explore the payload metabolites in an advanced PDAC population.
Recruiting1 award Phase 11 criteria
More about Jun Zhang
Clinical Trial Related5 years of experience running clinical trials · Led 28 trials as a Principal Investigator · 13 Active Clinical TrialsTreatments Jun Zhang has experience with
- Pembrolizumab
- Cisplatin
- Carboplatin
- Berzosertib
- Gemcitabine Hydrochloride
- Paclitaxel
Breakdown of trials Jun Zhang has run
Lung Cancer
Non-Small Cell Lung Cancer
Stomach Cancer
- Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jun Zhang specialize in?
Jun Zhang focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Jun Zhang currently recruiting for clinical trials?
Yes, Jun Zhang is currently recruiting for 7 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Jun Zhang has studied deeply?
Yes, Jun Zhang has studied treatments such as Pembrolizumab, Cisplatin, Carboplatin.
What is the best way to schedule an appointment with Jun Zhang?
Apply for one of the trials that Jun Zhang is conducting.
What is the office address of Jun Zhang?
The office of Jun Zhang is located at: Houston Methodist Hospital, Houston, Texas 77030 United States. This is the address for their practice at the Houston Methodist Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.